Respiration rates of the polyps of four jellyfish species: Potential thermal triggers and limits

AbstractThe bloom dynamics of metagenic jellyfish are regulated, to a large degree, by the asexual reproduction of benthic polyps. The ecophysiology of polyps is poorly studied compared to pelagic (ephyrae and medusae) life stages. We measured unfed (routine) respiration rates (RR) of the polyps of four scyphozoan species (Cyanea capillata, Aurelia aurita, Aurelia labiata and Aurelia limbata) acclimated to six temperatures between 7 and 20°C and one species (A. aurita) under hypoxic conditions. Strong increases (Q10~7 to 13) in RR occurred after subtle warming across specific test temperatures (e.g., 12 to 15°C for C. capillata, A. labiata, and A. aurita). In some species, RR at 20°C was lower than at 15 or 18°C suggesting that sub-optimally warm temperatures were approached. Polyps of A. aurita were unable to maintain RR below 11, 22 and 24% O2 saturation at 8.0, 15.5 and 19.0°C, respectively. Despite obvious differences in activity and habitat, rates of respiration in polyps, ephyrae and medusae of A. aurita at 15°C appear similar after taking into account differences in body size. A literature comparison of polyp respiration rates suggests a narrowing of thermal windows in individuals collected from higher latitudes. Common garden experiments are needed to thoroughly examine potential local adaptation

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

Background: Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse cardiovascular events (MACE) in people with overweight or obesity, but the effects of this drug on outcomes in patients with atherosclerotic cardiovascular disease and heart failure are unknown. We report a prespecified analysis of the effect of once-weekly subcutaneous semaglutide 2·4 mg on ischaemic and heart failure cardiovascular outcomes. We aimed to investigate if semaglutide was beneficial in patients with atherosclerotic cardiovascular disease with a history of heart failure compared with placebo; if there was a difference in outcome in patients designated as having heart failure with preserved ejection fraction compared with heart failure with reduced ejection fraction; and if the efficacy and safety of semaglutide in patients with heart failure was related to baseline characteristics or subtype of heart failure. Methods: The SELECT trial was a randomised, double-blind, multicentre, placebo-controlled, event-driven phase 3 trial in 41 countries. Adults aged 45 years and older, with a BMI of 27 kg/m2 or greater and established cardiovascular disease were eligible for the study. Patients were randomly assigned (1:1) with a block size of four using an interactive web response system in a double-blind manner to escalating doses of once-weekly subcutaneous semaglutide over 16 weeks to a target dose of 2·4 mg, or placebo. In a prespecified analysis, we examined the effect of semaglutide compared with placebo in patients with and without a history of heart failure at enrolment, subclassified as heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, or unclassified heart failure. Endpoints comprised MACE (a composite of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death); a composite heart failure outcome (cardiovascular death or hospitalisation or urgent hospital visit for heart failure); cardiovascular death; and all-cause death. The study is registered with ClinicalTrials.gov, NCT03574597. Findings: Between Oct 31, 2018, and March 31, 2021, 17 604 patients with a mean age of 61·6 years (SD 8·9) and a mean BMI of 33·4 kg/m2 (5·0) were randomly assigned to receive semaglutide (8803 [50·0%] patients) or placebo (8801 [50·0%] patients). 4286 (24·3%) of 17 604 patients had a history of investigator-defined heart failure at enrolment: 2273 (53·0%) of 4286 patients had heart failure with preserved ejection fraction, 1347 (31·4%) had heart failure with reduced ejection fraction, and 666 (15·5%) had unclassified heart failure. Baseline characteristics were similar between patients with and without heart failure. Patients with heart failure had a higher incidence of clinical events. Semaglutide improved all outcome measures in patients with heart failure at random assignment compared with those without heart failure (hazard ratio [HR] 0·72, 95% CI 0·60-0·87 for MACE; 0·79, 0·64-0·98 for the heart failure composite endpoint; 0·76, 0·59-0·97 for cardiovascular death; and 0·81, 0·66-1·00 for all-cause death; all pinteraction>0·19). Treatment with semaglutide resulted in improved outcomes in both the heart failure with reduced ejection fraction (HR 0·65, 95% CI 0·49-0·87 for MACE; 0·79, 0·58-1·08 for the composite heart failure endpoint) and heart failure with preserved ejection fraction groups (0·69, 0·51-0·91 for MACE; 0·75, 0·52-1·07 for the composite heart failure endpoint), although patients with heart failure with reduced ejection fraction had higher absolute event rates than those with heart failure with preserved ejection fraction. For MACE and the heart failure composite, there were no significant differences in benefits across baseline age, sex, BMI, New York Heart Association status, and diuretic use. Serious adverse events were less frequent with semaglutide versus placebo, regardless of heart failure subtype. Interpretation: In patients with atherosclerotic cardiovascular diease and overweight or obesity, treatment with semaglutide 2·4 mg reduced MACE and composite heart failure endpoints compared with placebo in those with and without clinical heart failure, regardless of heart failure subtype. Our findings could facilitate prescribing and result in improved clinical outcomes for this patient group. Funding: Novo Nordisk

Can Aurelia (Cnidaria, Scyphozoa) species be differentiated by comparing their scyphistomae and ephyrae?

Debate exists regarding the number of species of the moon jellyfish (genus Aurelia), a common member of the planktonic community of the coastal shelf seas around the world. Three Aurelia congeners (A. aurita, A. labiata and A. limbata) are currently considered to exist but recent genetic analyses suggested that this is an oversimplification. We analyzed the morphological characteristics of scyphistomae, morphological characteristics of ephyrae and differences in the time span of the strobilation process of Aurelia congeners from 17, 7 and 6 different source populations, respectively, of known species. Morphological characteristics of scyphistomae were similar among the 17 populations but those of ephyrae, such as the shape and form of lappets, were effective discriminators in the 6 cases examined. We recommend identifying species based on differences in 1) the morphological characteristics of scyphistomae and ephyrae (and not only medusae), 2) the genetics of individuals, and 3) the geographical occurrence of the population. This study adds to the growing body of knowledge on scyphozoan scyphistomae and ephyrae, stages of the metagenic life cycle of scyphozoans that have received relatively little study compared to medusae

Effects of food and CO2 on growth dynamics of polyps of two scyphozoan species (Cyanea capillata and Chrysaora hysoscella)

Increasing anthropogenic CO2 concentration in the atmosphere is altering sea water carbonate chemistry with unknown biological and ecological consequences. Whereas some reports are beginning to emerge on the effects of ocean acidification (OA) on fish, very little is known about the impact of OA on jellyfish. In particular, the benthic stages of metagenetic species are virtually unstudied in this context despite their obvious importance for bloom dynamics. Hence, we conducted tri-trophic food chain experiments using the algae Rhodomonas salina as the primary producer, the copepod Acartia tonsa as the primary consumer and the benthic life stage of the scyphozoans Cyanea capillata and Chrysaora hysoscella as secondary consumers. Two experiments were conducted examining the effects of different levels of CO2 and food quality (experiment 1) and the effect of food quality and quantity (experiment 2) on the growth and respiration of scyphozoan polyps. Polyp growth and carbon content (µg polyp−1) were not affected by the CO2 treatments, but were significantly negatively affected by P limitation of the food in C. capillata but not in Ch. hysoscella. Growth and carbon content were reduced in low-food treatments, but increased with decreasing P limitation in high- and low-food treatments in C. capillata. Respiration was not significantly influenced by food quality and quantity in C. capillata. We conclude that phosphorus can be a limiting factor affecting the fitness of scyphopolyps and that P-limited food is of poor nutritional quality. Furthermore, OA, at least using realistic end-of-century scenarios, will have no direct effect on the growth of scyphistoma